Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155945 · ClinicalTrials.gov registry record · Phase 2
Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03155945 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT03155945, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this randomized, open-label, parallel, phase 2a study is to determine the tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease experiencing abdominal pain.
Interventions
- DRUG Olorinab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2018-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03155945
The ClinicalTrials.gov registry entry for NCT03155945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olorinab is the first listed.
NCT03155945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03155945 about?
NCT03155945 is a clinical study titled "Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain". The purpose of this randomized, open-label, parallel, phase 2a study is to determine the tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease experiencing abdominal pain.
What is the current status of trial NCT03155945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-07-19. Estimated completion is 2018-09-10.
What interventions are being tested in trial NCT03155945?
The interventions under investigation include: Olorinab (DRUG).
Who is sponsoring clinical trial NCT03155945?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.